{"schema_version":"secwatch.filing_event.v1","accession":"0001062993-26-000819","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.017979+00:00","generated_at":"2026-05-16T03:04:45.948548+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"InMed Q2 FY2026 net loss $2.03M; cash drops to $7.0M; warns of material impact from pending US legislation on BayMedica","bullets":["Net loss of $2.03M for Q2 FY2026 (EPS -$0.51) vs net loss $2.58M in prior year; gross profit fell to $184K from $461K.","Cash and equivalents $7.0M at Dec 31, 2025 vs $11.1M at June 30, 2025; expects runway into Q4 calendar 2026.","BayMedica revenues $0.8M, down 26% YoY, due to pending US legislation H.R. 5371 that may prohibit certain cannabinoid sales after Nov 12, 2026.","INM-901 Alzheimer's candidate advanced: oral formulation showed robust bioavailability in large animal PK study; no adverse neural effects.","R&D expenses fell to $0.6M from $0.9M; expects substantial increase in H2 FY2026 for IND-enabling studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001062993-26-000819","json":"https://secwatch.observer/filing/0001062993-26-000819.json","markdown":"https://secwatch.observer/filing/0001062993-26-000819.md","text":"https://secwatch.observer/filing/0001062993-26-000819.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000106299326000819/0001062993-26-000819-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000106299326000819/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:04:45.948548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}